Literature DB >> 18430788

Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases.

Gabriel Birkus1, Nilima Kutty, Gong-Xin He, Andrew Mulato, William Lee, Martin McDermott, Tomas Cihlar.   

Abstract

9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) is an isopropylalaninyl phenyl ester prodrug of the nucleotide HIV reverse transcriptase inhibitor tenofovir (TFV; 9-[(2-phosphonomethoxy)propyl]adenine) exhibiting potent anti-HIV activity and enhanced ability to deliver parent TFV into peripheral blood mononuclear cells (PBMCs) and other lymphatic tissues in vivo. The present study focuses on the intracellular metabolism of GS-7340 and its activation by a variety of cellular hydrolytic enzymes. Incubation of human PBMCs in the presence of GS-7340 indicates that the prodrug is hydrolyzed slightly faster to an intermediate TFV-alanine conjugate (TFV-Ala) in quiescent PBMCs compared with activated cells (0.21 versus 0.16 pmol/min/10(6) cells). In contrast, the conversion of TFV-Ala to TFV and subsequent phosphorylation to TFV-diphosphate occur more rapidly in activated PBMCs. The activity of GS-7340 hydrolase producing TFV-Ala in PBMCs is primarily localized in lysosomes and is sensitive to inhibitors of serine hydrolases. Cathepsin A, a lysosomal serine protease has recently been identified as the primary enzyme activating GS-7340 in human PBMCs. Results from the present study indicate that in addition to cathepsin A, a variety of serine and cysteine proteases cleave GS-7340 and other phosphonoamidate prodrugs of TFV. The substrate preferences displayed by these enzymes toward TFV amidate prodrugs are nearly identical to their preferences displayed against oligopeptide substrates, indicating that GS-7340 and other phosphonoamidate derivatives of TFV should be considered peptidomimetic prodrugs of TFV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430788     DOI: 10.1124/mol.108.045526

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  33 in total

1.  Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy.

Authors:  Eisuke Murakami; Ting Wang; Yeojin Park; Jia Hao; Eve-Irene Lepist; Darius Babusis; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

Review 2.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

Review 3.  Clinical Pharmacology in HIV Therapy.

Authors:  Mohamed G Atta; Sophie De Seigneux; Gregory M Lucas
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-29       Impact factor: 8.237

4.  Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation.

Authors:  Nicholas A Lentini; Benjamin J Foust; Chia-Hung Christine Hsiao; Andrew J Wiemer; David F Wiemer
Journal:  J Med Chem       Date:  2018-09-26       Impact factor: 7.446

5.  Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.

Authors:  Kyle E Giesler; Jose Marengo; Dennis C Liotta
Journal:  J Med Chem       Date:  2016-07-22       Impact factor: 7.446

6.  Synthesis of a long acting nanoformulated emtricitabine ProTide.

Authors:  Dhruvkumar Soni; Aditya N Bade; Nagsen Gautam; Jonathan Herskovitz; Ibrahim M Ibrahim; Nathan Smith; Melinda S Wojtkiewicz; Bhagya Laxmi Dyavar Shetty; Yazen Alnouti; JoEllyn McMillan; Howard E Gendelman; Benson J Edagwa
Journal:  Biomaterials       Date:  2019-08-20       Impact factor: 12.479

7.  In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.

Authors:  Christian Callebaut; George Stepan; Yang Tian; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

8.  Relative bioavailability study of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy male fasted volunteers.

Authors:  Chengtao Lu; Yanyan Jia; Jing Yang; Ying Song; Wenxing Liu; Yi Ding; Xiaoli Sun; Aidong Wen
Journal:  Clin Drug Investig       Date:  2012-05-01       Impact factor: 2.859

9.  Role of cathepsin A and lysosomes in the intracellular activation of novel antipapillomavirus agent GS-9191.

Authors:  Gabriel Birkus; Nilima Kutty; Christian R Frey; Riri Shribata; Tsuifen Chou; Carston Wagner; Martin McDermott; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

10.  Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Selwyn J Hurwitz; Raymond F Schinazi
Journal:  Drug Discov Today Technol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.